证券代码：688399 证券简称：硕世生物 公告编号：2024-050 (三)投资期限 江苏硕世生物科技股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏硕世生物科技股份有限公司（以下简称"公司"或"硕世生物"）于 2024年10月25日召开第三届董事会第八次会议，第三届监事会第六次会议，审 议通过了《关于使用闲置自有资金进行现金管理的议案》，同意在不影响公司正 常经营及确保资金安全的情况下，拟使用暂时闲置自有资金不超过人民币 200,000万元（含本数）进行现金管理，上述额度自董事会审议通过议案并作出 决议之日起12个月内有效。在前述额度和期限范围内，可循环滚动使用。具体 情况如下： 一、本次使用闲置自有资金进行现金管理的情况 (一)投资目的 为提高自有资金的使用效率，维护上市公司和股东的利益，在保证正常经 营所需流动资金的情况下，提高资金利用效率，增加资金收益，公司对闲置自 有资金进行现金管理，用于投资安全性高、流动性好的理财产品。 (二)资金来源及额度 在确保不 ...

证券代码：688399 证券简称：硕世生物 公告编号：2024-048 江苏硕世生物科技股份有限公司 第三届监事会第六次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏硕世生物科技股份有限公司（以下简称"公司"）于 2024 年 10 月 25 日下午 14:00 以现场结合通讯方式召开第三届监事会第 六次会议（以下简称"本次会议"）。本次会议通知于 2024 年 10 月 18 日向各位监事发出，本次会议应到监事 3 人，实到监事 3 人。 本次会议的召集、召开程序均符合《公司法》《证券法》等法律、法 规和规范性文件以及《公司章程》的规定。 会议由监事会主席马施达先生主持，经与会监事充分讨论，会 议以记名投票方式审议通过了如下议案： 表决结果：同意 3 票、反对 0 票、弃权 0 票。 二、审议通过《关于使用闲置募集资金进行现金管理的议案》 监事会认为：公司本次使用部分暂时闲置募集资金进行现金管 理符合《上市公司监管指引第 2 号——上市公司募集资金管理和使 用的监管要求》《上海证券交易所科创板上市公 ...

证券代码：688399 证券简称：硕世生物 公告编号：2024-049 江苏硕世生物科技股份有限公司 关于使用闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏硕世生物科技股份有限公司（以下简称"公司"或"硕世生物"） 于2024年10月25日召开第三届董事会第八次会议，第三届监事会第六次会议， 审议通过了《关于使用闲置募集资金进行现金管理的议案》，同意公司在确 保不影响正常运营和募集资金投资项目建设的情况下，拟使用暂时闲置募集 资金不超过人民币22,000万元（含本数）进行现金管理，上述额度自董事会 审议通过议案并作出决议之日起12个月内有效。在前述额度和期限范围内， 可循环滚动使用。暂时闲置募集资金现金管理到期后将及时归还至募集资金 专户。具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意江苏硕世生物科技股份有限公 司首次公开发行股票注册的批复》(证监许可〔2019〕2224号)和上海证券交 易所自律监管决定书〔2019〕267号核准同意，公司首次公开发行人民币 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥90,639,768.40, representing a year-on-year increase of 0.92%[2]. - The net profit attributable to shareholders for the same period was -¥2,125,862.61, while the net profit for the year-to-date period increased by 115.40% to ¥27,114,657.29[2][7]. - The net profit for Q3 2024 was CNY 27,114,657.29, a significant recovery from a net loss of CNY 176,014,301.45 in the same period last year, marking a turnaround of over 115%[17]. - Operating profit for Q3 2024 reached CNY 33,048,345.37, compared to an operating loss of CNY 161,635,365.05 in Q3 2023, indicating a substantial improvement[17]. - The total profit for Q3 2024 was CNY 32,237,455.29, a significant recovery from a total loss of CNY -164,302,028.83 in Q3 2023[17]. - The company reported a net profit of CNY 2,537,690,516.95, slightly up from CNY 2,510,575,859.66, indicating a growth of about 1.1%[16]. Research and Development - Research and development (R&D) expenses totaled ¥25,913,873.43 in Q3 2024, a decrease of 14.03% compared to the same period last year, accounting for 28.59% of operating revenue[3]. - Research and development expenses for the first three quarters of 2024 were CNY 72,683,955.39, down from CNY 98,908,502.56, indicating a decrease of about 26.4%[16]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,856,866,778.45, a decrease of 1.27% from the end of the previous year[3]. - The company's total assets as of the end of Q3 2024 were CNY 3,856,866,778.45, slightly down from CNY 3,906,413,426.27 at the end of Q3 2023[16]. - Current liabilities increased to CNY 442,630,586.94 from CNY 363,869,054.38, reflecting an increase of approximately 21.6%[15]. - The company’s long-term liabilities decreased to CNY 127,237,259.14 from CNY 137,440,466.78, a reduction of approximately 7.9%[15]. - The total equity attributable to shareholders decreased by 3.47% to ¥3,286,998,932.37 compared to the end of the previous year[3]. - The total equity attributable to shareholders decreased to CNY 3,286,998,932.37 from CNY 3,405,103,905.11, a decline of approximately 3.5%[16]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥96,620,500.57, reflecting a significant increase of 134.83% compared to the same period last year[6]. - Cash flow from operating activities for the first three quarters of 2024 was CNY 96,620,500.57, a recovery from a negative cash flow of CNY -277,430,186.77 in the same period last year[18]. - The company reported a net cash outflow from investing activities of CNY -631,706,261.31 in the first three quarters of 2024, compared to a smaller outflow of CNY -477,806,688.84 in the same period last year[19]. - The company’s cash flow from financing activities showed a net outflow of CNY -3,568,567.41 in Q3 2024, contrasting with a net inflow of CNY 198,652,069.31 in Q3 2023[19]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,236[8]. - The largest shareholder, Shaoxing Runkang Biological Pharmaceutical Equity Investment Partnership, holds 15,600,000 shares, accounting for 26.61% of the total shares[9]. - The company completed a share buyback of 1,949,918 shares, representing 3.33% of the total share capital, with a total expenditure of RMB 150.0163 million[11]. - The company plans to use between RMB 150 million and RMB 300 million for share repurchase within three months from the approval date[11]. - The highest repurchase price during the buyback was RMB 90.00 per share, while the lowest was RMB 69.70 per share[11]. - The company has no significant changes in the top 10 shareholders due to securities lending or borrowing activities[10]. - The company’s total share capital is 58,620,000 shares[9]. Cost Management - The company has implemented cost reduction and efficiency enhancement measures, which have positively impacted net profit growth[6][7]. - Total operating costs decreased significantly to CNY 308,029,355.80 from CNY 437,980,740.76, representing a reduction of approximately 29.6%[16]. Inventory and Receivables - The company is focusing on optimizing accounts receivable collection and inventory turnover management to improve financial performance[7]. - Accounts receivable decreased to RMB 59,908,099.69 from RMB 108,714,894.80, indicating a decline of about 44.9%[12]. - The company’s inventory increased to CNY 100,168,273.87 from CNY 93,859,936.04, reflecting an increase of about 6.9%[14]. Foreign Exchange and Other Gains - Non-recurring gains and losses for Q3 2024 amounted to ¥12,213,993.69, with government subsidies contributing ¥10,994,161.40[4]. - The company experienced a foreign exchange loss of CNY -6,501,055.88 in Q3 2024, compared to a gain of CNY 7,500,948.92 in the same period last year[17].

Investment Rating - The report assigns an "Accumulate" rating for the company for the first time with a target price of 86.57 CNY [1][3]. Core Views - The company focuses on "Maternal and Child Health + Infectious Diseases" with strong R&D capabilities, particularly in the in vitro diagnostics (IVD) sector, and has shown continuous improvement in operational capabilities [2][3]. - The IVD industry is expected to grow steadily, with the domestic market projected to expand from 716 billion CNY in 2019 to 1,332 billion CNY by 2024, reflecting a CAGR of 13.2% [2][26]. - The company has established a leading position in molecular diagnostics and is actively developing its presence in point-of-care testing (POCT) and overseas markets [2][3]. Financial Performance - In 2024 H1, the company achieved revenue of 180 million CNY, a decrease of 4.9% year-on-year, but a 2.0% increase in regular business revenue when excluding COVID-19 impacts [2][19]. - The net profit attributable to the parent company for 2024 H1 was 29.24 million CNY, a significant increase of 143% year-on-year, marking a return to profitability [2][19]. - The gross margin reached 68.1% in 2024 H1, with a notable improvement in cost control leading to a net margin of 16.5% [2][23]. Market Position and Strategy - The company has over 600 products, primarily focusing on nucleic acid molecular diagnostic reagents, which accounted for 90.2% of its revenue in 2024 H1 [2][19]. - The company is a major supplier of nucleic acid testing products in the infectious disease sector and has a leading brand in the vaginal microecology evaluation system [2][3]. - The company is actively expanding its overseas market presence, with international sales growing by 34.4% in 2024 H1, and regular overseas business revenue increasing by over 150% when excluding COVID-19 impacts [2][19].

Investment Rating - The report initiates coverage on the company with an "Overweight" rating and a target price of 86.57 yuan [1] Core Views - The company is a leading player in nucleic acid molecular diagnostics, with a strong focus on women's health and infectious disease testing [2] - The company has a robust R&D capability, with over 600 products and a significant presence in the molecular diagnostics market [2] - The company has successfully diversified its product portfolio, including POCT and overseas market expansion, which has helped it achieve a turnaround in profitability [2] - The company's core technology platforms, including multiplex fluorescent quantitative PCR, NGS, and POCT, provide a competitive edge in the IVD market [2] Financial Performance - The company reported revenue of 1.8 billion yuan in H1 2024, a year-on-year decrease of 4.9%, but its regular business grew by 2.0% after excluding the impact of COVID-19-related business [2] - Net profit attributable to the parent company was 292.4 million yuan in H1 2024, a year-on-year increase of 143%, marking a turnaround from losses [2] - The gross margin in H1 2024 reached 68.1%, and the net profit margin improved to 16.5% due to better cost control [2] Industry Outlook - The domestic IVD market is expected to grow from 716 billion yuan in 2019 to 1,332 billion yuan in 2024, with a CAGR of 13.2% [2] - The molecular diagnostics market is projected to reach 25.8 billion yuan in 2024, driven by the rapid development of PCR and NGS technologies [2] - The company is well-positioned in the molecular diagnostics segment, with a strong presence in PCR-based testing and a leading market share in vaginal microecology evaluation systems [2] Product Portfolio - The company's product portfolio includes nucleic acid molecular diagnostic reagents, nucleic acid purification reagents, and immunodiagnostic reagents, with diagnostic reagents accounting for 90.2% of revenue in H1 2024 [2] - The company has developed a comprehensive range of products for infectious disease testing, including respiratory, intestinal, and bloodborne pathogens [12] - In the women's health segment, the company offers HPV testing, vaginal microecology evaluation, and reproductive health products, with its HPV testing business growing rapidly since 2016 [54] Overseas Expansion - The company has established branches in Hong Kong, the UK, and the US, and its overseas revenue in H1 2024 reached 52.8 million yuan, a year-on-year increase of 34.4% [19] - The company has successfully launched products for emerging infectious diseases such as monkeypox and dengue fever, with several products receiving international certifications [64] Technological Advancements - The company has developed a multiplex fluorescent quantitative PCR platform, which allows for high-throughput and cost-effective detection of multiple targets [33] - The company's SIC-1000 fully automated dry immunoassay analyzer, launched in H1 2024, offers rapid and accurate detection of respiratory pathogens, with results available in 16 minutes [45] - The company's HPV 21 genotyping and quantitative detection system uses a unique mathematical model to quantify viral load, providing more accurate screening for cervical cancer [39]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/7/1 | | --- | --- | | 回购方案实施期限 | 待股东大会审议通过后 3 个月 | | 预计回购金额 | 万元~30,000 万元 15,000 | | 回购价格上限 | 90 元/股 | | 回购用途 | √减少注册资本 □为维护公司价值及股东权益 | | 实际回购股数 | 万股 194.9918 | | 实际回购股数占总股本比例 | 3.33% | | 实际回购金额 | 万元 15,001.63 | | 实际回购价格区间 | 元/股~90.00 元/股 69.70 | 一、回购审批情况和回购方案内容 江苏硕世生物科技股份有限公司（以下简称"公司"）分别于 2024 年 6 月 28 日、2024 年 7 月 16 日召开了第三届董事会第四次会议和 2024 年第一次临时股东 大会，审议通过了《关于公司以集中竞价方式回购股份暨"提质增效重回报"行 动方案的议案》，同意公司自股东大会审议通过之日起 3 个月使 ...

上海市通力律师事务所关于江苏硕世生物科技股份有限公司 2024 年第三次临时股东大会的法律意见书 致:江苏硕世生物科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受江苏硕世生物科技股份有限公司 (以下简称"公司")的委托,指派本所茹秋乐律师、赵伯晓律师(以下简称"本所律 师")根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东大会 规则》等法律法规和规范性文件(以下统称"法律法规")及《江苏硕世生物科技股份 有限公司章程》(以下简称"公司章程")的规定就公司 2024 年第三次临时股东大会 (以下简称"本次股东大会")相关事宜出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以 了核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中 的所有签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、 完整和有效的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股东大会 人员资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表 ...

证券代码：688399 证券简称：硕世生物 公告编号：2024-045 江苏硕世生物科技股份有限公司 2024 年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 10 月 10 日 （二） 股东大会召开的地点：江苏省泰州市药城大道 837 号公司会议室 3、董事会秘书胡园园出席本次会议，公司高级管理人员列席本次会议，公 司聘请的见证律师列席本次会议。 二、 议案审议情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 104 | | --- | --- | | 普通股股东人数 | 104 | | 2、出席会议的股东所持有的表决权数量 | 25,069,630 | | 普通股股东所持有表决权数量 | 25,069,630 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 44.2 ...

(本页以下无正文) (本页无正文,为控股股东《关于江苏硕世生物科技股份有限公司股 票交易严重异常波动的询证函》的回函之签署页) 控股股东:绍兴闰康生物医药股权投资合伙企业(有限合伙) 执行事务合伙人(签字): 《关于江苏硕世生物科技股份有限公司 股票交易严重异常波动的询证函》的回函 致,江苏硕世生物科技股份有限公司: 贵公司《关于江苏硕世生物科技股份有限公司股票交易严重异常 波动的询证函》已收悉,作为贵公司控股股东,经核查,现回复如下: 截至目前本企业不存在应披露而未披露的重大信息,包括但不限 于正在筹划的并购重组、股份发行、债务重组、业务重组、资产剥离 和资产注入等重大事项。在本次股票交易严重异常波动期间不存在买 卖公司股票的情况。 20 24 年10月 /日 《关于江苏硕世生物科技股份有限公司 股票交易严重异常波动的询证函》的回函 致,江苏硕世生物科技股份有限公司: 贵公司《关于江苏硕世生物科技股份有限公司股票交易严重异常 波动的询证函》已收悉,作为贵公司实际控制人,经核查,现回复如 下: 截至目前本人不存在应披露而未披露的重大信息,包括但不限于 正在筹划的并购重组、股份发行、债务重组、业务重组、资产剥离 ...